Chief Executive Officer & Chief Medical Officer



Dr. Adnan H. Siddiqui, is Chief Executive Officer & Chief Medical Officer of the Jacobs Institute (JI). His goal is to improve the JI’s current offerings and translate technologies being developed in the Institute’s i2R, or idea to Reality Center, into therapeutic and commercial successes.



Dr. Adnan H. Siddiqui, is Chief Executive Officer & Chief Medical Officer of the Jacobs Institute (JI). His goal is to improve the JI’s current offerings and translate technologies being developed in the Institute’s i2R, or idea to Reality Center, into therapeutic and commercial successes.

Dr. Siddiqui is also vice-chairman and professor of neurosurgery at the State University of New York at Buffalo (UB) Jacobs School of Medicine and Biomedical Sciences. He is the director of neuroendovascular research and stroke service at Kaleida Health’s Gates Vascular Institute (GVI), and director of the UB Canon Stroke & Vascular Research Center (CSVRC). He is also a practicing surgeon with the University at Buffalo Neurosurgery (UBNS) which is part of of UBMD Physicians’ Group, a clinical practice where he sees and treats patients.

He completed fellowship training in interventional neuroradiology, cerebrovascular surgery, and neurocritical care from Thomas Jefferson University in Philadelphia. He completed his neurosurgical residency at Upstate Medical University and received his PhD in neuroscience from the University of Rochester and medical degree from Aga Khan University in Pakistan. He is a fellow of the American Association of Neurological Surgeons (AANS), American College of Surgeons (ACS), and American Heart Association (AHA), and member of the Society of Neurological Surgeons (Senior Society) and Academy of Neurological Surgeons (the Academy).

Dr. Siddiqui has over 450 peer reviewed publications, more than 50 chapters, almost 70,000 citations and an H index of 72. He is particularly proud of representing Buffalo and the US at most major cerebrovascular conferences around the world with over 200 international presentations to date. He has designed, conducted, and lead multiple major national and international clinical trials and currently serves as national and international principal investigator (PI) for multiple major funded multi-site trials. These efforts have significantly contributed to the success of the department, which was ranked 7th in academic impact in North America by the Journal of Neurosurgery.

He also serves as director of the Canon Stroke and Vascular Research Center (CSVRC) at UB. This multi-disciplinary center, with multiple concurrent major National Institute of Health (NIH) grants, houses neurosurgeons, neuroscientists, physicists and biomedical engineers working collaboratively on cutting edge research focused on neurovascular biology and pathology including stroke and aneurysms, imaging, simulation, and hemodynamics. He is the Fellowship Director for Buffalo’s prestigious Neuroendovascular Program. In addition, he serves as the director of the Neurosurgical Stroke Service at the GVI, one of the busiest Comprehensive Stroke Services in New York State and the US.

Dr. Siddiqui has continuously served on multiple scientific and educational committees of AANS, Congress of Neurological Surgeons (CNS) and Society of NeuroInterventional Surgery (SNIS). He is the chairman of the Joint Section of Cerebrovascular Surgery of the AANS and CNS and secretary for the SNIS. It has been a major focus for him to achieve consensus between the various organizations involved in fellowship training and credentialing for Neuroendovascular Surgery. He was a founding member of the Neuroendovascular Surgery Advisory Committee (NESAC) for Society of Neurological Surgery’s Committee for Advanced Sub-Specialty Training (CAST) and currently is a member of the American Board of Neurological Surgery’s (ABNS) Central Nervous System Endovascular Surgery Advisory Committee (CESAC). This has been an extremely important role, which is profoundly affecting the training and education pathways of neuroendovascular specialists.

He serves as a neurosurgeon director on the executive committee of the SNIS Patient Safety Organization which runs the NVQI-QOD Quality Outcomes Registry. He was nominated as a co-chair for the Devices for Acute Ischemic Stroke Intervention (DAISI) a Coordinated Registry network run collaboratively by the US Food and Drug Administration (FDA), Centers for Medicare and Medicaid Services (CMS), and NIH with partnership with physician societies and industry. He is committed to this singular opportunity to unify the multi-specialty neuroendovascular surgery field to develop robust prospective quality outcomes databases to shepherd the next generation of evidence-based practice. Recently, he has assumed the role of co-chair of the Neurological Devices Working group for the Medical Device Industry Consortium (MDIC), a not-for-profit group consisting of FDA, CMS, and industry partners dedicated to resuming Early Feasibility Studies (EFS) also known as First in Human studies in the US.

Dr. Siddiqui has special interest and expertise in the performance of complementary microsurgical, radiosurgical, and endovascular techniques for the comprehensive management of cerebrovascular conditions. This spectrum of disease includes aneurysms and arteriovenous malformations, as well as dural, cavernous, and spinal fistulae. He has special interests in endovascular management of acute ischemic stroke, as well as endovascular and microsurgical management of extracranial and intracranial vascular occlusive disease. Other clinical interests include endovascular management of intractable epistaxis, facial vascular malformations, head, neck, and brain tumor embolization, and microsurgical resection of skull base tumors. He is profoundly indebted to his mentors Nick Hopkins, Robert Rosenwasser, Charles Hodge, and Shirley Joseph in shaping his career as a dual-trained cerebrovascular surgeon, clinician scientist and entrepreneur.

All these efforts as a microsurgeon, endovascular surgeon, scientist, and trialist, have allowed Dr. Siddiqui to gain unique insights into a critical and rapidly evolving specialty. At the same time, these endeavors have required significant collaborations resulting in strong and trusting relationships with fellow neurosurgeons, neurologists, neuroradiologists, scientists, engineers, regulatory officers, and industry.

Dr. Siddiqui is married and has three children. He is a proud Buffalonian who is challenged and invigorated by taking care of neurosurgical patients and their families. He is most gratified by his pedagogical responsibilities, which allow him the opportunity to teach medical students, residents, and fellows. He is grateful for the opportunity to work at UB’s Department of Neurosurgery, CSVRC, GVI, and JI facilities, with some of the world’s best technologies and greatest vascular specialists, researchers, and biomedical engineers who are collaborating to advance the care of vascular diseases.

Conflict & Disclosure

Current Research Grants::

Co-investigator for NIH – 1R01EB030092-01, Project Title: High Speed Angiography at 1000 frames per second; Mentor for Brain Aneurysm Foundation Carol W. Harvey Chair of Research, Sharon Epperson Chair of Research, Project Title: A Whole Blood RNA Diagnostic for Unruptured Brain Aneurysm: Risk Assessment Prototype Development and Testing

Financial Interest/Investor/Stock Options/Ownership::

Adona Medical, Inc., Amnis Therapeutics, Bend IT Technologies, Ltd., BlinkTBI, Inc, Buffalo Technology Partners, Inc., Cardinal Consultants, LLC, Cerebrotech Medical Systems, Inc, Cerevatech Medical, Inc., Cognition Medical, CVAID Ltd., Endostream Medical, Ltd, Imperative Care, Inc., Instylla, Inc., International Medical Distribution Partners, Launch NY, Inc., NeuroRadial Technologies, Inc., Neurotechnology Investors, Neurovascular Diagnostics, Inc., PerFlow Medical, Ltd., Q’Apel Medical, Inc.,, Inc., Radical Catheter Technologies, Inc., Rebound Therapeutics Corp. (Purchased 2019 by Integra Lifesciences, Corp), Rist Neurovascular, Inc. (Purchased 2020 by Medtronic), Sense Diagnostics, Inc., Serenity Medical, Inc., Silk Road Medical, Spinnaker Medical, Inc., StimMed, LLC, Synchron, Inc., Three Rivers Medical, Inc., Truvic Medical, Inc., Vastrax, LLC, VICIS, Inc., Viseon, Inc.

Consultant/Advisory Board::

Amnis Therapeutics, Apellis Pharmaceuticals, Inc., Boston Scientific, Canon Medical Systems USA, Inc., Cardinal Health 200, LLC, Cerebrotech Medical Systems, Inc., Cerenovus, Cerevatech Medical, Inc., Cordis, Corindus, Inc., Endostream Medical, Ltd, Imperative Care, Integra, IRRAS AB, Medtronic, MicroVention, Minnetronix Neuro, Inc., Penumbra, Q’Apel Medical, Inc., Rapid Medical, Rebound Therapeutics Corp., Serenity Medical, Inc., Silk Road Medical, StimMed, LLC, Stryker Neurovascular, Three Rivers Medical, Inc., VasSol,, Inc., W.L. Gore & Associates

National PI/Steering Committees::

Cerenovus EXCELLENT and ARISE II Trial; Medtronic SWIFT PRIME, VANTAGE, EMBOLISE and SWIFT DIRECT Trials; MicroVention FRED Trial & CONFIDENCE Study; MUSC POSITIVE Trial; Penumbra 3D Separator Trial, COMPASS Trial, INVEST Trial, MIVI neuroscience EVAQ Trial; Rapid Medical SUCCESS Trial.